We believe the next revolution in cancer treatment is the development of allogeneic CAR T therapies, or AlloCARs, which are engineered from the T cells of healthy donors. These off-the-shelf CAR T therapies enhanced by gene editing could be the next most important breakthrough in the field. Our mission is to catalyze this immune cell therapy approach and deliver AlloCARs to patients with hematologic cancers and solid tumors to make a difference in their lives.
In April 2018, we completed a $300 million Series A financing, one of the largest in biotechnology, from a premier investment consortium that included Two River, TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer, Gilead and Pfizer.
Our portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an allogeneic CAR T therapy candidate currently in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).